Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy with or without AK117 versus placebo plus chemotherapy as first-line treatment for metastatic pancreatic cancer
CTR20251413Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab, ligufalimab in pancreatic adenocarcinoma (PDAC), sponsored by Akeso, Inc.. Started Jun 2025; status: active.
02
Drugs
ivonescimabligufalimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20251413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251413.